ClpP Inhibitors
1 drugsAbout ClpP
ClpP (Caseinolytic peptidase P) is a serine protease involved in protein homeostasis within cells, particularly in bacteria and mitochondria. It plays a crucial role in protein degradation and regulation, making it a potential target for therapeutic intervention.
Currently, there is no genetic evidence directly linking ClpP to specific diseases. However, the approval of MODEYSO suggests that ClpP modulation can be a viable therapeutic strategy.
ClpP is targeted by one FDA-approved drug, MODEYSO, a small molecule developed by CHIMERIX. The current therapeutic area for ClpP-targeting drugs falls into the 'Other' category.
Top ClpP Drugs
CHIMERIX is the only company with an approved drug targeting ClpP.
Low competition suggests a first-mover advantage, but also highlights potential risks in the target's viability.
ClpP Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ClpP, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like PROTACs.
ClpP Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ClpP. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 0 | 1 | 1 | 0% |
| Phase 2 | 3 | 0 | 3 | 0 | 0% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ClpP Drug Approval Timeline (2025 - 2025)
The first and most recent drug approval for ClpP was MODEYSO in 2025.
Recent approval indicates renewed interest, but further approvals are needed to confirm target viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ClpP. A trial counts if an approved drug acting on ClpP is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.